↑ 疾患リストへ　← 戻る

 38. スティーヴンス・ジョンソン症候群　［臨床試験数：10，薬物数：14（DrugBank：8），標的遺伝子数：9，標的パスウェイ数：92］ 

Searched query = "Stevens Johnson syndrome", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02987257December 20202 September 2019Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisPhase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in AdultsStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: cyclosporin A;Drug: Etanercept 50 MG Solution for Injection;Drug: PlacebosVanderbilt University Medical CenterUniversity of Ottawa;University of Toronto;Loyola University;University of South Florida;University of TexasNot recruiting18 YearsN/AAll267Phase 3United States
2NCT03585946September 1, 201816 July 2018Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisA Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug ReactionDrug: Site specific standard of care comparisonMassachusetts General HospitalNot recruiting18 YearsN/AAll750N/A
3JPRN-jRCTs06118004401/06/201722 July 2019Multicenter Open-trial of Steroid pulse therapy for SJS/TENMulticenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST StudyStevens-Johnson syndrome and Toxic epidermal necrolysis1. infusion of methylprednisolone at 500~1000 mg/d
(0.9% N/S in 3 hour) for 3 consecutive days.
2. Oral predonisolone (0.5 mg/kg/d) was initiated on the
day following the last dose of methylprednisolone, and
prednisolone was subsequently tapered within 2 weeks.
If the ocular involvement score is more than 2, dose of
oral predonisolone (1 mg/kg/d) is recommended.		Eishin MoritaRecruiting20 age old90 age oldBoth20Phase 2Taiwan;Germany
4NCT02126020November 201416 December 2017Topical Infliximab in Autoimmune Eyes With KeratoprosthesisTopical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane PemphigoidDrug: topical infliximabJames Chodosh, MD, MPHMassachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)Not recruiting18 Years80 YearsAll0Phase 1/Phase 2United States;Canada
5NCT02149732May 20142 May 2016Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet TransplantationAn Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency PatientsLimbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical BurnBiological: cultivated oral mucosal epithelial sheet transplantationSeoul National University HospitalMinistry of Health & Welfare, KoreaNot recruiting16 YearsN/ABothPhase 1/Phase 2Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT01696500October 201219 February 2015Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.Stevens-Johnson Syndrome;Toxic Epidermal NecrolysisDrug: Intravenous immunoglobulinNihon Pharmaceutical Co., LtdNot recruiting20 YearsN/ABoth10Phase 3Japan
7NCT01582880March 20124 November 2019Use of Cross-linked Donor Corneas as Carriers for the Boston KeratoprosthesisThe Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston KeratoprosthesisChemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune DiseasesDrug: RiboflavinJoseph B. Ciolino, MDNot recruiting18 YearsN/AAll1Phase 1/Phase 2United States
8NCT01256489December 201017 November 2015Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Corneal BlindnessDrug: InfliximabMassachusetts Eye and Ear InfirmaryNot recruiting18 YearsN/ABoth0Phase 1/Phase 2United States
9NCT02037347October 201019 October 2017Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisPalifermin Treatment of Toxic Epidermal NecrolysisToxic Epidermal Necrolysis;Stevens-Johnson SyndromeDrug: PaliferminBrett KingSwedish Orphan BiovitrumNot recruiting18 YearsN/AAll1Phase 1/Phase 2United States
10NCT01488396February 200719 February 2015Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry EyeEfficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry EyeStevens-Johnson SyndromeDrug: 0.05%cyclosporin eye dropMahidol UniversityNot recruiting18 YearsN/ABoth31Phase 4Thailand

先頭へ